Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ModraDoc006/r versus intravenous docetaxel in metastatic castration-resistant prostate cancer
2019-000582-21Phase 2Completed
- Sponsor
- Modra Pharmaceuticals
- Start
- Apr 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ModraDoc006, ritonavir and docetaxel in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Modra Pharmaceuticals. Primary endpoint: Radiographic progression-free survival. Started Apr 2019; status: completed.
02
Drugs
ModraDoc006ritonavirdocetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2019-000582-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000582-21.